Leadership & Pay ·
At its 2026 Annual Meeting held on June 10, 2026, Entrada Therapeutics, Inc. stockholders elected Peter S. Kim, Ph.D.…
TRDAEntrada Therapeutics, Inc.
At its 2026 Annual Meeting held on June 10, 2026, Entrada Therapeutics, Inc. stockholders elected Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. to the Board of Directors as Class II directors. Shareholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Additionally, the meeting resulted in the approval of Amendment No. 1 to the 2021 Stock Option and Incentive Plan and Amendment No. 1 to the 2021 Employee Stock Purchase Plan, both of which modify evergreen provisions to include outstanding pre-funded warrants in the share count calculations. Entrada Therapeutics, Inc. is a biotechnology company focused on therapeutic development.